Parabilis Medicines
Parabilis Medicines (formerly FOG Pharmaceuticals) is a clinical-stage biopharmaceutical company developing Helicon peptide therapeutics targeting undruggable intracellular protein targets. The company's lead candidate, FOG-001 (zolucatetide), is a first-in-class direct inhibitor of the β-catenin:TCF interaction for cancer treatment.
Public Company
Parabilis Medicines is publicly traded
IPO'd on Jun 9, 2026
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Employees
170–185
Total Funding
$1.48B
7 rounds
Last Private Valuation
$3.7B
Jun 9, 2026
Secondary Signals
2 signalsPriced upsized IPO at $20/share, raised $670M gross on Nasdaq under ticker PBLS
Public listing closes off private secondary-market trading in the name
Signed up-to-$2.3B Regeneron collaboration; Regeneron to buy ~$75M stock in concurrent private placement
Strategic-partner equity commitment ahead of IPO signals validation, not a liquidity event
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $1.48B across 7 rounds
Last updated 08-17-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Jun 9, 2026 | IPO | $670M | $3.7B | Not disclosed |
| Jan 8, 2026 | Series F Press release | $305M | — | RA Capital Management, Fidelity Management & Research Company, Janus Henderson Investors |
| Mar 2024 | Series E | $145M | — | Nextech Invest |
Prominent Investors
Leadership
Mathai Mammen
Chairman, CEO and President
Gregory Verdine
Co-Founder, former CEO (2015-2023), Chairman
Helen Ho
Chief Business and Strategy Officer
Tom Kotarakos
Chief Financial Officer
Fawzi Benzaghou
Chief Medical Officer
WeiQing Zhou
Co-founder, Chief Operating Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Gritstone bio
Clinical-stage biotech focused on immunotherapy and personalized medicine
Yumanity Therapeutics
Protein misfolding disorder therapeutic development
Calithera Biosciences
Metabolic oncology biotech
Agios Pharmaceuticals
Metabolism and rare genetic disorders
Parabilis Medicines Investment FAQ
Parabilis Medicines FAQ
Parabilis Medicines remains a private clinical-stage biopharmaceutical company with no announced IPO plans or public acquisition as of May 2026. Lead candidate FOG-001 (zolucatetide) in clinical development for cancer indications.
Parabilis Medicines shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Parabilis Medicines went public in Jun 9, 2026 via ipo, with an offering valuation of approximately $3.7B. Parabilis Medicines remains a private clinical-stage biopharmaceutical company with no announced IPO plans or public acquisition as of May 2026. Lead candidate FOG-001 (zolucatetide) in clinical development for cancer indications.
Parabilis Medicines raised $1.48B across 7 disclosed funding rounds prior to its public listing.
Parabilis Medicines was co-founded by Gregory Verdine, and WeiQing Zhou in 2015.
Parabilis Medicines is headquartered in Cambridge, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.